Biotechnology
Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On Obesity (E...
2025-05-06 16:55
2612
Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy
– Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund – Proceeds will support the Phase 1/2 clinical trial of lead candidate, NVC-001, in patients with LMNA-related d...
2025-05-06 13:00
2698
INTREPID Alliance Releases New Report Highlighting Urgent Gaps in Antiviral Preparedness
Global antiviral R&D is slowing when the world can least afford it, new analysis shows CAMBRIDGE, Mass., May 6, 2025 /PRNewswire/ -- The INTREPID Alliance today released the fourth edition of itsAntiviral Clinical and Preclinical Development Landscape, a comprehensive analysis of the global pi...
2025-05-06 02:16
1906
Genezen and Optieum Biotechnologies Partner to Support cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma
Collaboration supports manufacture of the OPTF01 product to Drive Next-Generation Chimeric Antigen Receptor T Cell (CAR-T) Development INDIANAPOLIS and EHIME, Japan, May 5, 2025 /PRNewswire/ -- Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Optieu...
2025-05-05 21:00
2107
IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance
SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial inthe United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation. NTS07...
2025-05-04 14:48
3146
Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
PHILADELPHIA, May 2, 2025 /PRNewswire/ -- Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the14th International Bone Morphogenetic Protein (BMP) Conference, taking ...
2025-05-02 19:30
2865
How latest genetic data on fertility may be an indicator of chronic disease onset and longevity
SINGAPORE, May 2, 2025 /PRNewswire/ -- Latest population studies have cast new light on genetic influences on women's reproductive lifespans and possible markers for the onset of chronic diseases. Evidence is growing that conditions such as cardiovascular disease, type 2 diabetes, rheumatoid a...
2025-05-02 15:59
3794
HistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion
SINGAPORE, May 2, 2025 /PRNewswire/ -- HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital pathology for the management of fibrotic diseases, has announced the close of a S$9 million inves...
2025-05-02 10:00
2871
A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis
SUZHOU, China, May 1, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody KN026 (Study ID: KN026-001) in combination with chemother...
2025-05-01 09:49
2961
S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial
SEOUL, South Korea, May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd.
2025-05-01 08:00
2711
ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care
Showcasing the future of ophthalmic research at ARVO 2025: * ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating research and clinical data, and simplifying research workflows. * ZEISS's collaboration with Boehring...
2025-04-30 21:00
2327
JediCare Medical has announced successful completion of its first-in-human feasibility study of the world's first-of-its-kind Pulmonary Nodule Percutaneous Sphere Resection
SHANGHAI, April 30, 2025 /PRNewswire/ -- JediCare Medical Technology Co., Ltd. a Shanghai, China based company ("the Company"), jointly with West China Hospital ofSichuan University, recently announced the successful completion of first-in-human ("FIH") feasibility study of its innovative, proprie...
2025-04-30 21:00
1984
Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting
SHANGHAI, April 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in poster format at the American Association for Cancer Research (AACR) annual meeting, held from Ap...
2025-04-30 20:00
2273
Genocury Biotech Annouces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency and durability. Results are attained without requiring lymphodepletion. SHENZHEN, China, April 30, 2025 /PRNewswire/ -- Genocury Biotech today revealed groundbreaking clinic...
2025-04-30 15:11
1916
Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting
SUZHOU, China, April 30, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American Association for Cancer Research (AACR) Annual Meetin...
2025-04-30 10:35
2684
Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies
SAN FRANCISCO and SUZHOU, China, April 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2025-04-30 08:00
2788
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong
SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Department of Health of the...
2025-04-30 07:45
2571
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
* Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations * Henlius to receive $31 million upfront, and up to $270 million in milestones SHANGHAI, April 29, 2025 /PRNewswire/ -- On April 29, 2025, Shanghai Henlius Biot...
2025-04-29 23:39
3049
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
* Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations * Henlius to receive $31 million upfront, and up to $270 million in milestones SHANGHAI, April 29, 2025 /PRNewswire/ -- On April 29, 2025, Shanghai Henlius Biot...
2025-04-29 23:38
2587
PHASE Scientific Earns Prestigious Recognition at 2025 ASCCP Scientific Meeting for Innovation in Urine-Based HPV Screening
SAN DIEGO, April 29, 2025 /PRNewswire/ -- PHASE Scientific (PHASE) proudly announced a major milestone this week with its inaugural participation and award-winning presentation at the 2025 American Society for Colposcopy and Cervical Pathology (ASCCP) Annual Scientific Meeting — one of the foremo...
2025-04-29 22:00
2413
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 306 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
6284
